Compare BioNano Genomics Inc (BNGO) vs Conagra Brands Inc (CAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Conagra Brands Inc — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Conagra Brands Inc trades at $15.05 (market cap $7.14B). The key difference: Conagra Brands Inc is far larger — about 522.7× BioNano Genomics Inc's market cap, and Conagra Brands Inc pays a 8.2% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | CAG | |
|---|---|---|
Market Cap | $13.66M | $7.14B |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $20.02 |
52-Week Low | $1.06 | $12.58 |
Enterprise Value | $16.26M | $14.20B |
Dividend Yield | — | 8.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Conagra Brands (CAG) trades at $15.06, up 1.89% with mixed technical signals showing neutral overall momentum. The company faces fundamental challenges with negative net income margin (-16.99%) and ROE (-25.06%) despite recent earnings beats. Recent developments include a 50% dividend cut to $0.18, new executive appointments, and strategic shifts under CEO John Brase to address margin pressure and declining sales.
While CAG's low valuation (P/E 10.06, P/S 0.63) offers potential upside, persistent revenue declines and margin compression present significant headwinds. Analyst consensus remains cautious with 62.5% hold ratings, though the company's debt reduction efforts and operational simplification could support a turnaround if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →
